使用人工智能的肿瘤疾病决策支持系统的应用与准确性：一项系统评价和荟萃分析

Use and accuracy of decision support systems using artificial intelligence for tumor diseases: a systematic review and meta-analysis.

作者信息

Oehring Robert, Ramasetti Nikitha, Ng Sharlyn, Roller Roland, Thomas Philippe, Winter Axel, Maurer Max, Moosburner Simon, Raschzok Nathanael, Kamali Can, Pratschke Johann, Benzing Christian, Krenzien Felix

机构信息

Department of Surgery, Charité - Universitätsmedizin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

Speech and Language Technology Lab, German Research Center for Artificial Intelligence (DFKI), Berlin, Germany.

出版信息

Front Oncol. 2023 Oct 4;13:1224347. doi: 10.3389/fonc.2023.1224347. eCollection 2023.

DOI:10.3389/fonc.2023.1224347

PMID:37860189

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10584147/

Abstract

BACKGROUND

For therapy planning in cancer patients multidisciplinary team meetings (MDM) are mandatory. Due to the high number of cases being discussed and significant workload of clinicians, Clinical Decision Support System (CDSS) may improve the clinical workflow.

METHODS

This review and meta-analysis aims to provide an overview of the systems utilized and evaluate the correlation between a CDSS and MDM.

RESULTS

A total of 31 studies were identified for final analysis. Analysis of different cancers shows a concordance rate (CR) of 72.7% for stage I-II and 73.4% for III-IV. For breast carcinoma, CR for stage I-II was 72.8% and for III-IV 84.1%, P≤ 0.00001. CR for colorectal carcinoma is 63% for stage I-II and 67% for III-IV, for gastric carcinoma 55% and 45%, and for lung carcinoma 85% and 83% respectively, all P>0.05. Analysis of SCLC and NSCLC yields a CR of 94,3% and 82,7%, P=0.004 and for adenocarcinoma and squamous cell carcinoma in lung cancer a CR of 90% and 86%, P=0.02.

CONCLUSION

CDSS has already been implemented in clinical practice, and while the findings suggest that its use is feasible for some cancers, further research is needed to fully evaluate its effectiveness.

摘要

背景

对于癌症患者的治疗规划，多学科团队会议（MDM）是必不可少的。由于讨论的病例数量众多以及临床医生的工作量巨大，临床决策支持系统（CDSS）可能会改善临床工作流程。

方法

本综述和荟萃分析旨在概述所使用的系统，并评估CDSS与MDM之间的相关性。

结果

共确定31项研究进行最终分析。对不同癌症的分析显示，I-II期的一致性率（CR）为72.7%，III-IV期为73.4%。对于乳腺癌，I-II期的CR为72.8%，III-IV期为84.1%，P≤0.00001。结直肠癌I-II期的CR为63%，III-IV期为67%；胃癌分别为55%和45%；肺癌分别为85%和83%，所有P>0.05。对小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC）的分析得出CR分别为94.3%和82.7%，P = 0.004；对肺癌中的腺癌和鳞状细胞癌分析得出CR分别为90%和86%，P = 0.02。